🔎 Trials Near Me

Utama › Leukemia Mielomonositik Kronik › Ohio

Kajian klinikal Leukemia Mielomonositik Kronik di Ohio

5 kajian untuk Leukemia Mielomonositik Kronik sedang mencari peserta di lokasi di Ohio.

Bandar di Ohio

Teks kajian rasmi (Bahasa Inggeris)

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

  • Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07249346

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06523556

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT04256317

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

  • Cleveland Clinic Cancer Center, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mac 2026 · NCT06543381

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • The Ohio State University Wexner Medical Center, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2025 · NCT03850574

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.